SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study

被引：9

作者：

Kyriakos, Georgios ^{[1
]}

Quiles-Sanchez, Lourdes, V ^{[2
]}

Garmpi, Anna ^{[3
]}

Farmaki, Paraskevi ^{[4
]}

Kyre, Konstantina ^{[5
]}

Savvanis, Spyridon ^{[6
]}

Antoniou, Vasileios K. ^{[7
]}

Memi, Eleni ^{[8
]}

机构：

[1] Hosp Gen Univ Santa Lucia, Secc Endocrinol & Nutr, Cartagena, Spain

[2] Ctr Salud Jesus Marin, Murcia, Spain

[3] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Med Sch, Internal Med Dept, Athens, Greece

[4] Natl & Kapodistrian Univ Athens, Aghia Sophia Childrens Hosp, Dept Pediat 1, Med Sch, Athens, Greece

[5] KAT Gen Hosp, Internal Med Dept, Athens, Greece

[6] Gen Hosp Athens Elpis, Dept Internal Med, Athens, Greece

[7] St Savvas Anticanc Hosp, Breast Surg Clin, Athens, Greece

[8] Ethnikon & Kapodistrian Univ Athens, Aretaieion Univ Hosp, Med Sch Athens, Unit Endocrinol Diabet Mellitus & Metab, Athens, Greece

来源：

CURRENT CARDIOLOGY REVIEWS | 2020年 / 16卷 / 04期

关键词：

SGLT2; inhibitors; T2DM; diabetes type 2 mellitus; EMPA-REG OUTCOME trial; CVD-REAL study; class effect; cardiovascular events; GLUCOSE COTRANSPORTER-2 INHIBITORS; HEART-FAILURE; DIABETES-MELLITUS; LOWERING DRUGS; EMPAGLIFLOZIN; RISK; MORTALITY; CANAGLIFLOZIN; SAFETY; DEATH;

D O I：

10.2174/1573403X15666190730094215

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied.

引用

页码：258 / 265

页数：8

共 50 条

[1] SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Abdul-Ghani, Muhammad
Del Prato, Stefano
Chilton, Robert
DeFronzo, Ralph A.
DIABETES CARE, 2016, 39 (05) : 717 - 725
[2] How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial
Wanner, Christoph
Nangaku, Masaomi
Kraus, Bettina J.
Zinman, Bernard
Mattheus, Michaela
Hantel, Stefan
Schumacher, Martin
Ohneberg, Kristin
Schmoor, Claudia
Inzucchi, Silvio E.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 (09) : 1504 - 1513
[3] Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial
Sharma, Abhinav
Ofstad, Anne Pernille
Ahmad, Tariq
Zinman, Bernard
Zwiener, Isabella
Fitchett, David H.
Wanner, Christoph
George, Jyothis T.
Hantel, Stefan
Desai, Nihar
Mentz, Robert J.
DIABETES, 2020, 69
[4] Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
Scheen, Andre J.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 121 : 204 - 214
[5] Increased grip strength with SGLT2 inhibitors: Sub-analysis by BMI, a new insight to EMPA-REG OUTCOME Study
Suzuki, Yoshihiko
Sano, Motoaki
Meguro, Shu
Kawai, Toshihide
Irie, Junichiro
Ikemura, Nobuhiro
DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S99 - S100
[6] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
Sharma, Abhinav
Inzucchi, Silvio E.
Testani, Jeffery
Ofstad, Anne Pernille
Fitchett, David
Mattheus, Michaela
Verma, Subodh
Zannad, Faiez
Wanner, Christoph
Kraus, Bettina
INTERNIST, 2022, 63 (SUPPL 3): : 316 - 316
[7] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
Sharma, A.
Inzucchi, S. E.
Testani, J.
Ofstad, A. P.
Fitchett, D.
Mattheus, M.
Verma, S.
Zannad, F.
Wanner, C.
Kraus, B. J.
EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 175 - 175
[8] Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes Insights From the EMPA-REG OUTCOME Trial
Sharma, Abhinav
Ofstad, Anne Pernille
Ahmad, Tariq
Zinman, Bernard
Zwiener, Isabella
Fitchett, David
Wanner, Christoph
George, Jyothis T.
Hantel, Stefan
Desai, Nihar
Mentz, Robert J.
JACC-HEART FAILURE, 2021, 9 (08) : 568 - 577
[9] Patient phenotypes and SGLT-2 inhibition in type 2 diabetes: insights from the EMPA-REG OUTCOME trial
Sharma, A.
Ofstad, A. P.
Ahmad, T.
Zinman, B.
Zwiener, I.
Fitchett, D.
Wanner, C.
George, J. T.
Hantel, S.
Desai, N.
Mentz, R. J.
DIABETOLOGIA, 2020, 63 (SUPPL 1) : S271 - S272
[10] Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
Scheen, A. J.
Delanaye, P.
DIABETES & METABOLISM, 2017, 43 (02) : 99 - 109

← 1 2 3 4 5 →